These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37853331)

  • 41. Perinatal risk factors associated with severity of haemolytic disease of the foetus and newborn due to Rhc maternal-foetal incompatibility: A retrospective cohort study.
    Franchinard L; Maisonneuve E; Friszer S; Toly Ndour C; Huguet-Jacquot S; Maurice P; Mailloux A; Cortey A; Jouannic JM
    Vox Sang; 2022 Apr; 117(4):570-579. PubMed ID: 34743337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Perinatal management and neurological outcome of newborns hospitalized with Rhesus hemolytic disease].
    Gobalakichenane P; Lardennois C; Galène-Gromez S; Brossard V; Marpeau L; Verspyck E; Marret S;
    Gynecol Obstet Fertil; 2008 Oct; 36(10):984-90. PubMed ID: 18804397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exchange transfusions in severe Rh-mediated alloimmune haemolytic disease of the foetus and newborn: a 20-year overview on the incidence, associated risks and outcome.
    Ree IMC; Besuden CFJ; Wintjens VEHJ; Verweij JEJT; Oepkes D; de Haas M; Lopriore E
    Vox Sang; 2021 Oct; 116(9):990-997. PubMed ID: 33730387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland.
    Susila S; Ilmakunnas M; Lauronen J; Vuorinen P; Ångerman S; Sainio S
    Transfusion; 2024 May; 64 Suppl 2():S119-S125. PubMed ID: 38240146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Haemolytic disease of the fetus and newborn/HDFN/timing in pregnant women and prophylaxis].
    Kulinska R
    Akush Ginekol (Sofiia); 2014; 53(2):58-63. PubMed ID: 25098112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anemic Disease of the Newborn With Little Increase in Hemolysis and Erythropoiesis Due to Maternal Anti-Jr
    Katsuragi S; Ohto H; Yoshida A; Otake A; Tsuneyama H; Ogasawara K; Isa K; Ikeda T
    Transfus Med Rev; 2019 Jul; 33(3):183-188. PubMed ID: 31227265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statistical model for prediction of ABO hemolytic disease of the fetus and newborn in India.
    Patale DS; Lokhande TL; Chaudhary RK
    Immunohematology; 2021 Jun; 37(2):64-68. PubMed ID: 34170645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-D in Rh positive pregnancies.
    Prasad MR; Krugh D; Rossi KQ; O'Shaughnessy RW
    Am J Obstet Gynecol; 2006 Oct; 195(4):1158-62. PubMed ID: 17000249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful use of maternal blood in the management of severe hemolytic disease of the fetus and newborn due to anti-Kp(b).
    Bleile MJ; Rijhsinghani A; Dwyre DM; Raife TJ
    Transfus Apher Sci; 2010 Dec; 43(3):281-283. PubMed ID: 20951648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors associated with persistence of red blood cell antibodies in woman after pregnancies complicated by fetal alloimmune haemolytic disease treated with intrauterine transfusions.
    Verduin EP; Brand A; van de Watering LM; Claas FH; Oepkes D; Lopriore E; Doxiadis II; Schonewille H
    Br J Haematol; 2015 Feb; 168(3):443-51. PubMed ID: 25244566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Title: Effect of multiple maternal red cell alloantibodies on the occurrence and severity of Hemolytic Disease of the Fetus and Newborn.
    Singh B; Chaudhary R; Katharia R
    Transfus Apher Sci; 2021 Feb; 60(1):102958. PubMed ID: 33039278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population-based incidence and risk factors for cholestasis in hemolytic disease of the fetus and newborn.
    Teng J; Wickman L; Reilly M; Nemeth A; Fischler B; Bohlin K; Tiblad E
    J Perinatol; 2022 Jun; 42(6):702-707. PubMed ID: 35194159
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case of Hemolytic Disease of the Fetus and Newborn Treated Without Blood Products.
    Hirschman L; Munchel A
    J Pediatr Hematol Oncol; 2024 Jan; 46(1):e118-e120. PubMed ID: 38032187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility.
    Smith HM; Shirey RS; Thoman SK; Jackson JB
    Immunohematology; 2013; 29(4):127-30. PubMed ID: 24689681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemolytic disease of the fetus and newborn caused by anti-s
    Lopez GH; Emthip M; Suwanwootichai P; Millard GM; Wilson B; Onpuns S; Laemsri K; Chiewsilp P; Flower RL; Hyland CA; Liew YW
    Transfusion; 2022 Oct; 62(10):2137-2142. PubMed ID: 36062546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemolytic disease of the fetus and newborn due to alloanti-M: three Chinese case reports and a review of the literature.
    Li S; Mo C; Huang L; Shi X; Luo G; Ji Y; Fang Q
    Transfusion; 2019 Jan; 59(1):385-395. PubMed ID: 30520533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Jk3 alloantibodies during pregnancy-blood bank management and hemolytic disease of the fetus and newborn risk.
    Lawicki S; Coberly EA; Lee LA; Johnson M; Eichbaum Q
    Transfusion; 2018 May; 58(5):1157-1162. PubMed ID: 29479723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management.
    Slootweg YM; Lindenburg IT; Koelewijn JM; Van Kamp IL; Oepkes D; De Haas M
    Am J Obstet Gynecol; 2018 Oct; 219(4):393.e1-393.e8. PubMed ID: 30063902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence and Risk Factors of Cholestasis in Newborns with Hemolytic Disease-A Case-Control Study.
    Drozdowska-Szymczak A; Mazanowska N; Pomianek T; Ludwin A; Krajewski P
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892901
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.